NZ513922A - Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione - Google Patents

Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione

Info

Publication number
NZ513922A
NZ513922A NZ513922A NZ51392201A NZ513922A NZ 513922 A NZ513922 A NZ 513922A NZ 513922 A NZ513922 A NZ 513922A NZ 51392201 A NZ51392201 A NZ 51392201A NZ 513922 A NZ513922 A NZ 513922A
Authority
NZ
New Zealand
Prior art keywords
dione
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
NZ513922A
Inventor
Jai Patel
Jeffrey Roger Granett
Hamish Ross
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NZ513922A publication Critical patent/NZ513922A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolodine-2, 4-dione and a process for it's preparation, characterized in that the composition comprises a unit dose of 2 to 8 mg of the above compound in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefore. Also described is the use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolodine-2, 4-dione in the manufacture of a medicament that is useful in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.
NZ513922A 1997-06-05 2001-09-03 Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione NZ513922A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
NZ513922A true NZ513922A (en) 2001-09-28

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ523725A NZ523725A (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione
NZ513922A NZ513922A (en) 1997-06-05 2001-09-03 Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ523725A NZ523725A (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (en)
JP (1) JP2001521553A (en)
KR (1) KR20010013410A (en)
CN (3) CN1112926C (en)
AP (1) AP1214A (en)
AR (2) AR015120A1 (en)
AU (1) AU8215098A (en)
BG (1) BG104048A (en)
BR (1) BR9810405A (en)
CA (2) CA2333352A1 (en)
CO (1) CO4940400A1 (en)
DZ (1) DZ2510A1 (en)
EA (1) EA002384B1 (en)
GB (1) GB9711683D0 (en)
HU (1) HUP0004070A3 (en)
ID (1) ID24264A (en)
IL (1) IL133074A0 (en)
MX (1) MXPA99011322A (en)
NO (2) NO995938L (en)
NZ (2) NZ523725A (en)
OA (1) OA11306A (en)
PE (1) PE78899A1 (en)
PL (1) PL337201A1 (en)
SK (1) SK164899A3 (en)
TR (2) TR199902963T2 (en)
TW (1) TW570797B (en)
UY (1) UY25032A1 (en)
WO (1) WO1998055122A1 (en)
ZA (2) ZA9811572B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200929A3 (en) 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
PE20010044A1 (en) * 1999-04-23 2001-03-10 Smithkline Beecham Plc SALT POLYMORPH OF MALEIC ACID OF 5- [4- [2- (N-METHYL-N- (2-PYRIDYL) AMINO) ETHOXY] BENZYL] -THAZOLIDINE-2,4-DIONA
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2294980T1 (en) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. ACID 2-N- (5 - ((4- (2- (METHYL-2-PYRIDINYLAMINE) ETHOXY) PHENYL) METHYL) -2,4-THIAZOLIDINDIONA) -BUTANODIOIC, PREPARATION PROCEDURES AND COMPOSITIONS WITH ROSIGLITAZONA MALEATE.
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
JPH11510508A (en) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー Methods for reducing the amount of exogenous insulin administered to non-insulin dependent diabetes mellitus patients
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
BR9710272A (en) * 1996-07-12 1999-08-10 Smithkline Beecham Plc New leptin resistance treatment

Also Published As

Publication number Publication date
CN1430959A (en) 2003-07-23
HUP0004070A2 (en) 2002-02-28
NO20040738L (en) 2000-02-02
TW570797B (en) 2004-01-11
PL337201A1 (en) 2000-08-14
CO4940400A1 (en) 2000-07-24
CA2333352A1 (en) 1998-12-10
CA2292629A1 (en) 1998-12-10
OA11306A (en) 2003-10-22
IL133074A0 (en) 2001-03-19
CN1526391A (en) 2004-09-08
WO1998055122A1 (en) 1998-12-10
AR015120A1 (en) 2001-04-18
SK164899A3 (en) 2000-11-07
BR9810405A (en) 2000-08-29
NO995938L (en) 2000-02-02
CA2292629C (en) 2004-01-06
ZA984826B (en) 1999-08-03
TR200002790T2 (en) 2001-11-21
ZA9811572B (en) 1999-07-22
TR199902963T2 (en) 2000-02-21
AR008198A1 (en) 1999-12-29
PE78899A1 (en) 1999-10-22
BG104048A (en) 2000-07-31
KR20010013410A (en) 2001-02-26
EA199901116A1 (en) 2000-06-26
AP1214A (en) 2003-10-08
MXPA99011322A (en) 2004-12-02
JP2001521553A (en) 2001-11-06
DZ2510A1 (en) 2003-01-25
AP9901696A0 (en) 1999-12-31
CN1259050A (en) 2000-07-05
EP0998284A1 (en) 2000-05-10
ID24264A (en) 2000-07-13
AU8215098A (en) 1998-12-21
CN1112926C (en) 2003-07-02
EA002384B1 (en) 2002-04-25
GB9711683D0 (en) 1997-08-06
HUP0004070A3 (en) 2002-03-28
NZ523725A (en) 2004-09-24
UY25032A1 (en) 1998-11-26
NO995938D0 (en) 1999-12-03

Similar Documents

Publication Publication Date Title
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
RU98117673A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF HYPERGLYCEMIA, MALIC ACID SALT 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZyl] THIAZOLI-IODIOLIENE-2-ILCENE-2-ILCENE-2-I-DIOLIDE-2-ILCENE-2-I-DOLIENE-2-ILCENE-2-ILCENE-2-I-2-Iolide-2-alkylene-2-imidene-2-dimene-2-amino-didene 2-amino-dione-in-2-d-imidene-2-amino-2-amino and 2-amino-2-inolin-2-amino inl and inlITin-2 in. TYPE II DIABETES TREATMENT FORM
KR940006590A (en) Compounds useful for treating Alzheimer's disease and as hypoglycemic agents
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
AR015894A1 (en) USE OF 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] TIAZOLIDIN-2,4-DIONA AND INSULIN FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINS SUCH COMPOUNDS
HUP0100500A2 (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino) ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt, process for its preparation and its pharmaceutical use
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY26112A1 (en) 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDINE-2,4-DIONA HYDROCHLORIDE
HUP0003397A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes
PE108199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA
HUP9900320A3 (en) Optically active thiazolidinone derivatives, preparation thereof, pharmageutical compositions containing these compounds as active ingredients and use of thia-or oxazolidine derivatives for preparation of pharmaceutical compositions
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
AR023563A1 (en) HYDROCLORIDE MONOHIDRATE OF A THIAZOLIDIN-2,4-DIONA DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
MXPA02012100A (en) Thiazolidinedione salt for treatment of diabetes mellitus.
GB0021784D0 (en) Novel pharmaceutical
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
HRP20010344B1 (en) Novel method of treatment
YU14503A (en) Novel pharmaceutical
HUP0003673A2 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
ECSP003434A (en) NEW COMPOUNDS
TH50263A (en) New therapies

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed